Optimization of Polyarginine-Conjugated PEG Lipid Grafted Proliposome Formulation for Enhanced Cellular Association of a Protein Drug
The purpose of this study was to develop an oral proliposomal powder of protein using poly-<span style="font-variant: small-caps;">l</span>-arginine-conjugated 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) (PLD) for enhancing cellular associat...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_a7dfdbc09f014feeb8a76d4dee1e67e8 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Amolnat Tunsirikongkon |e author |
700 | 1 | 0 | |a Yong-Chul Pyo |e author |
700 | 1 | 0 | |a Dong-Hyun Kim |e author |
700 | 1 | 0 | |a Sang-Eun Lee |e author |
700 | 1 | 0 | |a Jeong-Sook Park |e author |
245 | 0 | 0 | |a Optimization of Polyarginine-Conjugated PEG Lipid Grafted Proliposome Formulation for Enhanced Cellular Association of a Protein Drug |
260 | |b MDPI AG, |c 2019-06-01T00:00:00Z. | ||
500 | |a 1999-4923 | ||
500 | |a 10.3390/pharmaceutics11060272 | ||
520 | |a The purpose of this study was to develop an oral proliposomal powder of protein using poly-<span style="font-variant: small-caps;">l</span>-arginine-conjugated 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG) (PLD) for enhancing cellular association upon reconstitution and to compare its effects with a non-grafted and PEGylated formulation. Cationic proliposome (CATL), PLD-grafted CATL (PLD-CATL), PEGylated CATL (PEG CATL), and PLD grafted-PEG CATL (PLD-PEG CATL) were prepared and compared. Successful conjugation between poly-<span style="font-variant: small-caps;">l</span>-arginine and DSPE-PEG was confirmed by <sup>1</sup>H NMR and FT-IR. PLD was successfully grafted onto the proliposomal powder during the slurry process. Although reconstituted liposomal sizes of CATL and PLD-CATL were increased by agglomeration, PEGylation reduced the agglomeration and increased the encapsulation. The viabilities of cells treated with both CATL and PLD-CATL formulations were low but increased following PEGylation. With regard to cellular association, PLD-CATL enhanced cellular association/uptake more rapidly than did CATL. Upon PEGylation, PEG CATL showed a lower level of cellular association/uptake compared with CATL while PLD-PEG CATL did not exhibit the rapid cellular association/uptake as seen with PLD-CATL. However, PLD-PEG CATL still enhanced the higher cellular association/uptake than PEG CATL did without PLD. In conclusion, proliposomes with PLD could accelerate cellular association/uptake but also caused high cellular toxicity. PEGylation reduced cellular toxicity and also changed the cellular association pattern of the PLD formulation. | ||
546 | |a EN | ||
690 | |a poly-<span style="font-variant: small-caps">l</span>-arginine | ||
690 | |a DSPE-PEG | ||
690 | |a cationic proliposome | ||
690 | |a cellular association | ||
690 | |a cytotoxicity | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutics, Vol 11, Iss 6, p 272 (2019) | |
787 | 0 | |n https://www.mdpi.com/1999-4923/11/6/272 | |
787 | 0 | |n https://doaj.org/toc/1999-4923 | |
856 | 4 | 1 | |u https://doaj.org/article/a7dfdbc09f014feeb8a76d4dee1e67e8 |z Connect to this object online. |